CARE
Carter Bankshares, Inc.
CARE's fundamentals are strong: revenue grew 77% and its operating margin rose 36 points to 63%. At 4.9x earnings, it's trading less than half its usual 12x. Its downside scenario is about eight times its upside.
IREN
IREN Limited
There isn't enough reported data to score IREN yet.
CARE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
CARE's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like CARE.
IREN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| N/A | |
| N/A |
IREN's revenue and profitability are currently under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IREN.
CARE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 4.9x | $29.10 | — |
| Cheap | 6.8x | $39.97 | +37% |
| Fair | 12x | $69.41 | +139% |
| Forward | 12x | $29.10 | — |
| Expensive | 21x | $122 | +318% |
Historical ranges are pointers, not guarantees.
CARE's PE is in its cheap range at 4.9x. Analysts expect earnings to fall, which would put today's price at 12x next year's earnings, in its fair range.
IREN PE Valuation
IREN has no meaningful PE right now: it lost money over the past year.
CARE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong decline | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect CARE's earnings and revenue to decline, with profitability weakening.
IREN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
IREN has the edge over CARE on the outlook, with more favorable revenue and profitability expectations.
CARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.37 | -60% |
| Q3 2026 | $5.92 | +335% |
| Q2 2026 | $5.81 | +327% |
| Q1 2026 | $4.87 | +306% |
| Q4 2025 | $1.38 | +30% |
| Q3 2025 | $1.36 | +116% |
| Q2 2025 | $1.36 | +147% |
| Q1 2025 | $1.20 | +107% |
| Q4 2024 | $1.06 | +6% |
CARE has the edge over IREN on earnings quality, reporting a profit while its opponent remains loss making.
IREN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.96 | -347% |
| Q2 2026 | -$2.22 | -988% |
| Q1 2026 | $0.51 | +$1.10 |
| Q4 2025 | $1.18 | +$1.62 |
| Q3 2025 | $1.60 | +$1.99 |
| Q2 2025 | $0.25 | +$0.45 |
| Q1 2025 | -$0.59 | -$0.43 |
| Q4 2024 | -$0.44 | -$0.15 |
IREN has swung to a loss: it lost $3.96 per share over the past year, after a profit the year before.
CARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $46.2M | +18% |
| Q2 2026 | $68.7M | +84% |
| Q1 2026 | $106.9M | +189% |
| Q4 2025 | $39.8M | +15% |
| Q3 2025 | $39.1M | +14% |
| Q2 2025 | $37.3M | +11% |
| Q1 2025 | $37M | +11% |
| Q4 2024 | $34.5M | +13% |
CARE's revenue has grown year over year for 10 quarters in a row: $46M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | -4.5 points |
| Q2 2026 | 54% | +26 points |
| Q1 2026 | 103% | +73 points |
| Q4 2025 | 28% | -3.1 points |
| Q3 2025 | 18% | -2.2 points |
| Q2 2025 | 29% | +11 points |
| Q1 2025 | 30% | +8.4 points |
| Q4 2024 | 31% | +37 points |
CARE has the edge over IREN on profitability, with a higher operating margin.
IREN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $228M | -5.1% |
| Q2 2026 | $137.2M | -27% |
| Q1 2026 | $144.8M | 0% |
| Q4 2025 | $184.7M | +59% |
| Q3 2025 | $240.3M | +355% |
| Q2 2025 | $187.3M | +230% |
| Q1 2025 | $144.8M | +168% |
| Q4 2024 | $116.1M | +176% |
IREN's revenue has held roughly level: $228M last quarter, down 5.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -82% | -50 points |
| Q2 2026 | -452% | -461 points |
| Q1 2026 | -161% | -180 points |
| Q4 2025 | -63% | -79 points |
| Q3 2025 | -32% | +57 points |
| Q2 2025 | 9% | +49 points |
| Q1 2025 | 19% | +8 points |
| Q4 2024 | 15% | +21 points |
IREN's operating margin was −82% last quarter, down 50 points from the same quarter a year ago.
CARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5K | -100% |
| Q2 2026 | -$262.9M | -3522% |
| Q1 2026 | $302.4M | +6131% |
| Q4 2025 | $9M | +8.2% |
| Q3 2025 | $10.3M | +22% |
| Q2 2025 | $7.7M | +$12M |
| Q1 2025 | $4.9M | -70% |
| Q4 2024 | $8.3M | +37% |
CARE has the edge over IREN on cash generation, producing positive trailing cash flow while its opponent burns cash.
IREN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6B | -$1.6B |
| Q2 2026 | $482.2M | +2895% |
| Q1 2026 | -$873.8M | -$523.1M |
| Q4 2025 | -$468M | -$334M |
| Q3 2025 | -$38M | +$349.4M |
| Q2 2025 | $16.1M | +$179M |
| Q1 2025 | -$350.7M | -$128.7M |
| Q4 2024 | -$134M | -$105.2M |
IREN's free cash flow was −$2.5B over the past year, against −$507M the year before. Free cash flow isn't a meaningful measure for financial services companies like IREN.
CARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -37.2K shares |
| 1 year | -2.2% | -493K shares |
| 3 years | -5% | -1.1M shares |
| 5 years | -17% | -4.5M shares |
CARE has the edge over IREN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $2.2M |
| Q4 2025 | $6M |
| Q3 2025 | $4.9M |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
IREN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +82.4M shares |
| 1 year | +10% | +36.9M shares |
| 3 years | +511% | +333M shares |
| 5 years | +624% | +344M shares |
| Available history | +2346% | +382M shares |
IREN has 399M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
CARE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -1.6x | Net Cash |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | -0.8x | Net Cash |
| Q4 2024 | -1.6x | Net Cash |
CARE has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like CARE.
IREN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 157.6x | High |
| Q4 2025 | 22.2x | High |
| Q3 2025 | 4.1x | High |
| Q2 2025 | 2.0x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | -4.6x | Net Cash |
| Q3 2024 | -16.7x | Net Cash |
| Q2 2024 | -15.9x | Net Cash |
IREN's net debt is more than 20 years of its operating earnings (EBITDA), up from 3.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like IREN.
CARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.9 | Neutral |
| Stochastic | 7.8 | Oversold |
CARE's weekly RSI is 48 (neutral) and its Stochastic is 8 (oversold).
IREN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.3 | Neutral |
| Stochastic | 8.2 | Oversold |
IREN's weekly RSI is 33 (neutral) and its Stochastic is 8 (oversold).
CARE PE vs Financial Services Sector
| Metric | CARE | Sector median | Relative |
|---|---|---|---|
| PE | 4.9x | 13x | 62% below |
| PE % | 0 | 63 | 63 pts below |
CARE is trading at 4.9x earnings, a 62% discount to the Financial Services sector's median of 13x.
IREN PE vs Financial Services Sector
| Metric | IREN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IREN has no meaningful PE right now: it lost money over the past year.
CARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.9 | 2.5% below |
| 20 week MA | $31.4 | 7.4% below |
| 50 week MA | $26.6 | 9.3% above |
| 100 week MA | $22.0 | 32% above |
| 200 week MA | $18.4 | 59% above |
CARE has the edge over IREN on trend strength, trading above more of its moving averages.
IREN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.8 | 35% below |
| 20 week MA | $36.2 | 46% below |
| 50 week MA | $42.8 | 54% below |
| 100 week MA | $32.0 | 39% below |
| 200 week MA | $19.1 | 2.1% above |
IREN has fallen below most of its moving averages, though it's still 2.1% above its 200-week average.
CARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.3 | $10.8 | -54% |
| 2021 | $10.8 | $14.9 | +39% |
| 2022 | $14.9 | $16.7 | +12% |
| 2023 | $16.7 | $15.0 | -11% |
| 2024 | $15.0 | $17.6 | +18% |
| 2025 | $17.6 | $19.9 | +13% |
| 2026 YTD | $19.9 | $29.1 | +46% |
CARE has the edge over IREN on returns for 2026, with the stronger performance.
IREN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $24.8 | $17.2 | -31% |
| 2022 | $17.2 | $1.19 | -93% |
| 2023 | $1.19 | $7.15 | +501% |
| 2024 | $7.15 | $10.7 | +50% |
| 2025 | $10.7 | $40.3 | +276% |
| 2026 YTD | $40.3 | $19.5 | -52% |
IREN's yearly returns have swung widely, from +501% in 2023 to −93% in 2022. It's down 52% so far in 2026.